Articles by John Mascarenhas, MD
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Two experts discuss the role of surrogate end points in MPN clinical trials.
Discussing current clinical trials iand unmet needs in myelofibrosis.
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.